• In late May 2026, Adaptive Biotechnologies announced that its NGS-based clonoSEQ MRD test was featured in 33 presentations, including a plenary and 14 oral sessions, at the ASCO Annual Meeting in Chicago and the EHA Congress in Stockholm, underscoring its FDA-cleared, CE-marked and Medicare-covered role in hematologic cancer care.
• The breadth of data across multiple myeloma, CLL, ALL and lymphomas highlights how clonoSEQ’s high-sensitivity MRD testing is increasingly embedded in real-world practice, clinical trials and MRD-guided treatment decisions across the US and Europe.
• We’ll now examine how clonoSEQ’s expanding use as a “gold standard” MRD tool across major cancers could influence Adaptive’s investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Adaptive Biotechnologies Investment Narrative Recap

To own Adaptive Biotechnologies, you need to believe clonoSEQ can become a durable standard in MRD testing while the company narrows losses without heavy dilution. The ASCO/EHA data blitz reinforces clonoSEQ’s clinical relevance and may support the near term MRD revenue catalyst, but it does little to change the central risk that Adaptive remains unprofitable at the consolidated level and may still depend on capital markets if cash burn does not keep improving.

The most relevant recent announcement alongside ASCO/EHA is Adaptive’s Q1 2026 update, where MRD revenue guidance was lifted to US$260–270 million for the year. That higher outlook, coupled with MRD segment EBITDA positivity, ties directly to clonoSEQ’s growing presence in major trials and real world care. Together, they frame how stronger test adoption could support revenue scale, while the company still works to prove that improved unit economics can eventually translate into overall profitability.

However, beneath this progress, investors should also be aware that prolonged company wide losses could still lead to ...

Adaptive Biotechnologies' narrative projects $451.6 million revenue and $70.4 million earnings by 2029. This requires 15.2% yearly revenue growth and a $120.1 million earnings increase from -$49.7 million today.

Uncover how Adaptive Biotechnologies' forecasts yield a $20.14 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue near US$447.1 million and a small profit by 2029, so if clonoSEQ’s ASCO and EHA momentum outpaces those expectations or if regulatory and cost risks from heavy R&D spending bite harder than they assume, your view on Adaptive’s upside or downside could look very different from theirs.

Explore 3 other fair value estimates on Adaptive Biotechnologies - why the stock might be worth as much as 27% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Adaptive Biotechnologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adaptive Biotechnologies' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.